The relevance of miRNAs as promising biomarkers in lip cancer

Assáo, Agnes; Domingues, Maria Aparecida Custódio; Minicucci, Eliana Maria; Marchi, Fábio Albuquerque; Coutinho‐Camillo, Cláudia Malheiros; Oliveira, Denise Tostes

doi:10.1007/s00784-020-03773-9

Cited by 8 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preoperative imaging investigations are crucial adjunctive tools in the initial assessment of high-risk patients with SCC, in addition to the evaluation of the signs and symptoms of PNI ( 37 ). Magnetic resonance imaging (MRI) or CT are the most commonly used methods for radiographic imaging of PNI ( 38 ). Based on the presence of nerve enhancement or enlargement, or the absence of the typical fat plane surrounding a nerve, MRI can detect the extent of macroscopic disease ( 39 ).…”

Section: Metastasismentioning

confidence: 99%

Metastatic patterns and treatment options for head and neck cutaneous squamous cell carcinoma (Review)

Iancu,

Fulga,

Vesa

et al. 2024

Mol Clin Oncol

View full text Add to dashboard Cite

According to current predictions, one-fifth of all Americans will develop skin cancer during their lifetime. Cutaneous squamous cell carcinoma (cSCC) most commonly occurs in the head and neck region, which is the area of the body with the highest level of sun exposure. High-risk head and neck cSCC (HNcSCC) is a broad category with numerous high-risk factors that are associated with unfavorable results. In cSCC staging systems, clinical and tumor traits that are likely to result in poor outcomes are identified. Metastasis occurs in ~2.5% of patients with cSCC, most often in the local lymph nodes, and there is some indication that lymph node metastasis has a distinct pattern based on the tumor site. Current findings on tumor molecular targets have suggested the use of systemic treatments, particularly immunotherapy (such as cemiplimab, pembrolizumab and nivolumab), over radiotherapy or chemotherapy for this type of metastasis. However, when used simultaneously with immunotherapy, radiotherapy may be beneficial in the treatment of metastatic HNcSCC by improving the efficacy of immunotherapy. The present review aims to assess the existing literature on metastatic HNcSCC pathways and treatment options, in order to define current and future directions. Notably, there is an urgent need to identify patients who may benefit from local or systemic cancer treatments. The treatment of lymph node metastasis presents a therapeutic challenge and requires comprehensive management.

show abstract

Section: Metastasismentioning

confidence: 99%

Metastatic patterns and treatment options for head and neck cutaneous squamous cell carcinoma (Review)

Iancu,

Fulga,

Vesa

et al. 2024

Mol Clin Oncol

View full text Add to dashboard Cite

show abstract

“…The study conducted by Assao et al, to check expression levels of miR-181b, miR-21, miR-31, and miR-345 in actinic cheilitis with and without epithelial dysplasia and with lower lip squamous cell carcinomas (LLSCC), revealed that increased expression of miR-345, miR-181b, and miR-31 was found in actinic cheilitis without epithelial dysplasia, in comparison with that of actinic cheilitis with epithelial dysplasia and LLSCC (Figure 1). Thus, this miRNA signature can help to identify actinic cheilitis, with the potential to progress to lip cancer [100].…”

Section: Lip Cancermentioning

confidence: 99%

Emerging Role of miR-345 and Its Effective Delivery as a Potential Therapeutic Candidate in Pancreatic Cancer and Other Cancers

et al. 2021

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with high mortality, poor prognosis, and palliative treatments, due to the rapid upregulation of alternative compensatory pathways and desmoplastic reaction. miRNAs, small non-coding RNAs, have been recently identified as key players regulating cancer pathogenesis. Dysregulated miRNAs are associated with molecular pathways involved in tumor development, metastasis, and chemoresistance in PDAC, as well as other cancers. Targeted treatment strategies that alter miRNA levels in cancers have promising potential as therapeutic interventions. miRNA-345 (miR-345) plays a critical role in tumor suppression and is differentially expressed in various cancers, including pancreatic cancer (PC). The underlying mechanism(s) and delivery strategies of miR-345 have been investigated by us previously. Here, we summarize the potential therapeutic roles of miR-345 in different cancers, with emphasis on PDAC, for miRNA drug discovery, development, status, and implications. Further, we focus on miRNA nanodelivery system(s), based on different materials and nanoformulations, specifically for the delivery of miR-345.

show abstract

“…Numerous biomarkers are being utilized, including circulating tumor DNA (ctDNA), micro RNAs, extracellular vesicles, circulating tumor cells and endothelin receptor type B hypermethylation [14,15]. More than one-hundred salivary components have been reported to differ in concentration in patients with and without OSCC [16,17].…”

Section: Introductionmentioning

confidence: 99%